These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9218913)

  • 1. Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response.
    Jones RN; Dudley MN
    Diagn Microbiol Infect Dis; 1997 May; 28(1):5-18. PubMed ID: 9218913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ampicillin-sulbactam susceptibility testing criteria.
    Barry A; Pfaller M; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):469-72. PubMed ID: 8359171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.
    Bradford PA; Sanders CC
    Antimicrob Agents Chemother; 1993 Feb; 37(2):251-9. PubMed ID: 8452355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Apr; 26(4):750-4. PubMed ID: 3130390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broth-disk elution tests to predict the susceptibility of anaerobic bacteria to the ampicillin-sulbactam combination.
    Jones RN
    Diagn Microbiol Infect Dis; 1990; 13(4):353-5. PubMed ID: 2076598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN; Barry AL; Thornsberry C; Wilson HW
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
    Zerva L; Biedenbach DJ; Jones RN
    J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.
    Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
    Eur J Clin Microbiol Infect Dis; 1993 May; 12(5):356-62. PubMed ID: 8354303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of clinical isolates of Haemophilus influenzae to ampicillin-sulbactam.
    Mortensen JE; LaRocco M; Himes SL; Inderlied C; Daly JA; Campos JM; Mendelman PM
    Diagn Microbiol Infect Dis; 1990; 13(4):341-4. PubMed ID: 2076596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of sulbactam/ampicillin against ampicillin-resistant, beta-lactamase-producing bacteria isolated in Italian hospitals.
    Varaldo PE; Ripa S; Nicoletti G; Covelli I; Satta G; Carlone N; Fontana R
    Chemotherapy; 1990; 36(2):141-6. PubMed ID: 2178890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
    Gill CJ; Ponticas S; Shungu DL; Guerriero S
    Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Jan; 26(1):13-7. PubMed ID: 3343304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.
    Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1984 Feb; 19(2):134-9. PubMed ID: 6321543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Shungu DL; Ponticas S; Gill CJ
    Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.
    Jones RN; Sutton LD; Cantrell HF; Lankford RB
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):143-9. PubMed ID: 7874881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ampicillin-sulbactam and amoxicillin-clavulanate susceptibility testing of Escherichia coli isolates with different beta-lactam resistance phenotypes.
    Oliver A; Pérez-Vázquez M; Martínez-Ferrer M; Baquero F; De Rafael L; Cantón R
    Antimicrob Agents Chemother; 1999 Apr; 43(4):862-7. PubMed ID: 10103192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.
    Bradford PA; Sanders CC
    Antimicrob Agents Chemother; 1992 Feb; 36(2):394-400. PubMed ID: 1605604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical laboratory approach for estimating effective administrative dose of sulbactam/cefoperazone].
    Uete T; Matsuo K
    Jpn J Antibiot; 1988 Nov; 41(11):1578-90. PubMed ID: 3210296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.